

disks of different sizes was 33.8 μ moles/kg.¹² In this test, the O-methylnordehydrobufotenine (IIc) is approximately twice as active as mescaline (ED_{50} = 71.0 μ moles/kg),¹¹ but is much less active than its open-chain analog, N,N-dimethyl-5-methoxytryptamine, which from published data^{5,8} can be estimated to be much more than 30 times as active a hallucinogen as mescaline. When injected subcutaneously into NIH general purpose white mice, IIc at 20 mg/kg causes only slight overt changes (reduction in spontaneous activity) while N,N-dimethyl-5-methoxytryptamine at 10 mg/kg causes profound effects. At this dosage the mice lose the ability to move normally and engage in locomotor activity with legs extended laterally.

Experimental Section¹³

5-Methoxy-4-nitrogramine (Ia).—A stirred mixture of 35 g (0.1713 mole) of 5-methoxygramine and 100 ml of AcOH was cooled to 10° and treated dropwise with a solution of 30 ml of concentrated HNO₃ (*d* 1.42) and 50 ml of AcOH over 30 min. The mixture was allowed to warm to room temperature, stirred overnight, and then diluted with 1 l. of ice-water. The resulting precipitate was filtered off, washed (H₂O), and dried. Recrystallization of the crude Ia from MeOH yielded 4.5 g (54%) of yellow-brown needles, mp 158–195.5°. The nmr spectrum was consistent with the structure. *Anal.* (C₁₂H₁₃N₃O₃) C, H, N.

5-Methoxy-4-nitroindolyl-3-acetonitrile (Ib).—A solution of 4.0 g (0.016 mole) of Ia and 0.5 ml of AcOH in 100 ml of dry THF was added dropwise to an ice-cold, stirred solution of 13 ml of Me₂SO₄ and 0.5 ml of AcOH in 50 ml of dry THF during 30 min. The resulting mixture was allowed to warm slowly to room temperature and to stand for 15 hr. The product was collected by filtration, washed (dry Et₂O), and then dried *in vacuo* over CaCl₂ to yield 4.5 g of methosulfate, mp 120–168°.

A mixture of 4.5 g of crude methosulfate, 120 ml of a NaOAc–HOAc buffer (3.0 g of AcOH and 4.1 g of NaOAc in 500 ml of H₂O), a few milliliters of Et₂O, and 4.0 g of NaCN was stirred at room temperature for 20 hr. The mixture was extracted (CH₂Cl₂), and the extract was washed (H₂O, dilute AcOH, saturated NaCl) and then dried (Na₂SO₄). After removal of the solvent, the crude product was recrystallized (MeOH) to yield 2.5 g (68%, based on Ib) of nitrile, mp 198.5–199.5°. *Anal.* (C₁₁H₉N₃O₃) C, H, N.

5-Methoxy-1,3,4,5-tetrahydropyrrolo[4,3,2-*d,e*]quinoline (IIa). Reductive Cyclization of 5-Methoxy-4-nitroindolyl-3-acetonitrile. (A) A mixture of 2 g (0.0086 mole) of Ib, 1 g of 10% Pd–C, and 250 ml of EtOAc was shaken with H₂ at 3.87 kg/cm² for 6 hr at 65° and for 15 hr at room temperature, and then filtered through Celite. After removal of the solvent, the crude product was recrystallized from Et₂O–petroleum ether (bp 30–60°) to yield 80 mg of fine white needles of 5-methoxy-4-aminoindolyl-3-acetonitrile (Ic), mp 142–143°. The white crystalline compound turned dark blue when exposed to air overnight. *Anal.* (C₁₁H₁₁N₃O) C, H, N.

(B) The reaction conditions employed for reductive cyclization of 5-methoxy-4-nitroindolyl-3-acetonitrile were identical with method A except that EtOH was used as the solvent. The product was purified in the same manner and eluted from a silica gel column with PhH–Et₂O (4:1) to yield 350 mg of solid which was recrystallized from Et₂O–petroleum ether to give 140 mg of colorless crystalline needles, mp 105–105.5°, of IIa. The nmr spectrum was consistent with the structure. *Anal.* (C₁₁H₁₂N₃O) C, H, N.

The second fraction, eluted from the silica gel with ether, was recrystallized from Et₂O–petroleum ether to give 50 mg of color-

less crystalline needles, mp 170–171°. The structure of this compound was assigned as 7-methoxy-1,2,3,4,5,6-hexahydropyrrolo[4,3,2-*d,e*]quinoline (III). The molecular weight determined by mass spectrometry was 190. The nmr spectrum was consistent with the structure. *Anal.* (C₁₁H₁₄N₃O) C, H, N.

(C) A mixture of 4.0 g of 5-methoxy-4-nitroindolyl-3-acetonitrile, 4.0 g of 10% Pd–C, and 300 ml of EtOH was hydrogenated for 4 hr at 65° at H₂ pressure of 3.87 kg/cm². The mixture was filtered and washed with 20 ml of EtOH. After the EtOH was removed, the blue-pink residue was chromatographed over silica gel to give the only identifiable product, IIa (0.8 g).

6-Methoxy-5-formyl-1,3,4,5-tetrahydropyrrolo[4,3,2-*d,e*]quinoline (IIb).—To 2 ml of formic-acetic anhydride, cooled in an ice bath, was added slowly 300 mg (0.0016 mole) of IIa. The solution was stirred at room temperature for 2 hr. After Et₂O (4 ml) was added and the solution was stirred for an additional 16 hr, it was diluted (H₂O), and then extracted (CH₂Cl₂). The extract was washed (H₂O, dilute NH₄OH, NaCl solution), dried (Na₂SO₄), and concentrated *in vacuo*. The yield of crude formyl derivative was 220 mg. The crude product was recrystallized from EtOH–Et₂O to give a white crystalline solid, mp 145–146°. *Anal.* (C₁₂H₁₂N₃O₂) C, H, N.

O-Methylnordehydrobufotenine (IIc).—To 5 ml of 1.0 *M* borane in THF (0.005 mole of BH₃) at room temperature was added dropwise, with stirring, a solution of 180 mg (0.0083 mole) of IIb in 10 ml of THF. The solution was stirred at room temperature for 24 hr. MeOH (10 ml) was added cautiously to the reaction mixture, followed by 10 ml of 5% aqueous NaOH. The solution was extracted (CHCl₃) and dried (Na₂SO₄). After the solvent was removed *in vacuo*, the residue was recrystallized from hexane to give 100 mg of white crystalline solid: mp 84.5–85.5°; mass spectrum mol wt, 202; nmr, 3.00 (triplet, 3-CH₂), 3.40 (triplet, 4-CH₂), 3.25 (singlet, NCH₃), 3.90 (OCH₃), 6.61 (doublet, *J* = 8 cps, C-8 H), 6.60 (singlet, C-2 H), 6.79 (doublet, *J* = 8 cps, C-7 H), and 7.68 (indole NH). *Anal.* (C₁₂H₁₃N₃O) C, H, N.

Acknowledgment.—The authors wish to acknowledge Dr. Bernhard Witkop for the original suggestion of this problem and Dr. Solomon Snyder for his assistance in obtaining pharmacological testing.

2-Amino-3-phenyl-1,1,1-trifluoropropanes. Fluorine Analogs of Amphetamines

ROGER M. PINDER, ROGER W. BRIMBLECOMBE,
AND DAVID M. GREEN

*Chemical Defence Experimental Establishment,
Porton Down, Salisbury, Wiltshire, England*

Received August 23, 1968

The trifluoromethyl group is well suited because of its unique chemical and physiological stability^{1,2} to replace the methyl group in known pharmacologically active compounds. Since a CF₃ group appears to be approximately the same size as CH₃,³ amphetamines with CH₃ replaced by CF₃ should have the same steric requirements. However, the strong electron-withdrawing properties of CF₃ will alter the basicity of the adjacent amino moiety. Similar analogs of α -methylphenylalanines, such as α -trifluoromethyl-dopa, have been claimed to be as active as the parent α -methyl compounds but with more specific effects.⁴ We are therefore reporting the synthesis and some pharmacology of a series of 2-amino-3-methoxylated-phenyl-1,1,1-

(12) The authors are indebted to Dr. Uyeno for the pharmacologic testing (Stanford Research Institute Research Fund) and for allowing us to report his findings.

(13) Melting points are corrected. Where analyses are indicated by symbols of the elements, analytical results were obtained within $\pm 0.4\%$ of the theoretical values. Spectral data were in agreement with assigned structures. Nmr data are reported in ppm from a TMS internal standard in CDCl₃ unless otherwise noted. Mass spectra were obtained with an AEI MS-9 mass spectrometer. Petroleum ether used had bp 30–60°.

(1) M. B. Chenoweth and L. P. McCarty, *Pharmacol. Rev.*, **15**, 673 (1963).

(2) N. P. Buu-Hoi, *Progr. Drug Res.*, **3**, 9 (1961).

(3) J. Lazar and W. A. Shepherd, *J. Med. Chem.*, **11**, 138 (1968).

(4) M. Sletzing and W. A. Gaines (to Merck and Co., Inc.), U. S. Patent 3,046,300 (1962).

trifluoropropanes, fluorine analogs of methoxyamphetamines in which the α -CH₃ has been replaced by CF₃.

The title compounds were synthesized by the route used by Pinder and Burger⁵ for 2-amino-3-phenyl-1,1,1-trifluoropropane itself. Several of the intermediates have been described in the patent literature,⁴ but in our hands the method reported for hydrolysis of the α -trifluoroacetylphenylacetone nitriles to the benzyl trifluoromethyl ketones gave only intractable tars. Furthermore, no physical data are given in the patent and we are reporting these for the first time.

The results of the pharmacological tests indicate that no amphetamine-like activity could be detected in a variety of tests designed to elicit behavioral responses. None of the title compounds displayed the typical central-stimulating effects of amphetamine in whole animals. However, the 3,4,5-trimethoxyphenyl derivative (**6**), in the head twitch test, showed activity of a type associated with hallucinogenic drugs; its activity in this respect was about one-tenth that of mescaline.

The results of this study and those of similar investigations⁵ indicate that replacement of CH₃ by CF₃ in phenethylamine-type molecules has a deleterious effect on biological activity. Patent claims⁴ indicating the beneficial effects of such substitutions have not been substantiated.⁶ The difference in size between CH₃ and CF₃ is not such that it would be responsible for completely abolishing biological activity, particularly since both 1-ethyl- and 1-ethynylphenethylamine, with α groups of larger dimensions⁷ than those of CF₃, are active as inhibitors of monoamine oxidase and as promoters of locomotor activity.⁸ Furthermore, 1-cyanophenethylamine, where the α substituent is identical in size with the ethynyl group but with very different electronic characteristics, is without amphetamine-like activity.⁹ It therefore seems that electronic considerations must play the major part in determining the biological activity of α -substituted phenethylamines. Certainly, the electron-withdrawing effect of CF₃ is sufficient to reduce the basicities of the amphetamines by almost 5pK_a units, as, for example, in amphetamine (pK_a = 9.93)¹⁰ and **1** (pK_a = 4.97) and 3,4-dimethoxyamphetamine (pK_a = 9.60)¹¹ and **4** (pK_a = 5.00). α substitution by the nitrile group has an even greater effect, 1-cyanophenethylamine having a pK_a of 4.70. This sequence compares well with that in the aliphatic analogs, where basicity increases in the order aminoacetonitrile (pK_a = 5.3),¹² 2,2,2-trifluoroethylamine (pK_a = 5.7),¹³ and ethylamine (pK_a = 10.75). Conversely, α substitution by CH₃ scarcely affects basicity, amphetamine being only slightly more basic than phenethylamine (pK_a = 9.86).¹⁰ We must conclude that α substitution of phenethylamines by strong electron-withdrawing groups such as CF₃ or CN severely reduces the availability of the

TABLE I
 α -TRIFLUOROACETYLPHENYLACETONITRILES

R	Yield, %	Mp, °C ^a	Formula ^b
3-OCH ₃	69	79–80.5	C ₁₁ H ₈ F ₃ NO ₂ ·H ₂ O
4-OCH ₃	61	73–74	C ₁₁ H ₈ F ₃ NO ₂ ·H ₂ O
3,4-(OCH ₃) ₂	63	151–152	C ₁₂ H ₁₀ F ₃ NO ₃
3,5-(OCH ₃) ₂	83	86–87	C ₁₂ H ₁₀ F ₃ NO ₃
3,4,5-(OCH ₃) ₃	80	136–137	C ₁₃ H ₁₂ F ₃ NO ₄ ·H ₂ O

^a Recrystallized from C₆H₆. ^b All compounds were analyzed for C, H, N. Their ir and nmr spectra were as expected.

lone pair of electrons of the amino nitrogen, and this factor is responsible for the lack of biological activity in such compounds. However, it also seems possible that lack of activity in the CNS is due to the decreased ability of such compounds to pass the blood-brain barrier.

Experimental Section

Melting points were determined in a Gallenkamp capillary melting point apparatus and are corrected. Where analyses are indicated only by symbols of the elements, analytical results obtained for those elements were within $\pm 0.4\%$ of the theoretical values. pK_a values were determined potentiometrically using a Radiometer Titrograph SBR 2c, and are accurate to ± 0.05 unit.

α -Trifluoroacetylphenylacetone nitriles (Table I).—In a typical preparation, a mixture of 3,4,5-trimethoxyphenylacetone nitrile (20.7 g, 0.1 mole) and CF₃CO₂Et (14.2 g, 0.1 mole) in EtOH (100 ml) was added over 30 min to a gently refluxing solution of Na (2.3 g, 0.1 g-atom) in EtOH (30 ml). The whole was heated under reflux for 14 hr. The cold dark red solution was poured into a mixture of concentrated HCl (20 ml) and H₂O (500 ml), extracted with Et₂O (two 250-ml portions), washed (H₂O), and dried (MgSO₄). Distillation gave a red oil which was crystallized from C₆H₆, yield 26 g.

Benzyl Trifluoromethyl Ketones (Table II).—Typically, α -trifluoroacetyl(3,4,5-trimethoxy)phenylacetone nitrile hydrate (16.1 g, 0.05 mole) was added to a mixture of 98% H₂SO₄ (85 g) and H₂O (50 ml) in a flask equipped with a 30-cm unpacked insulated column. The mixture was heated to 180–200° and steam distillation from the top of the column began at 95–98°. H₂O was added slowly from the dropping funnel at such a rate that the temperature was maintained at 100°. After 6 hr, the distillate was extracted with Et₂O, dried (MgSO₄), and distilled under reduced pressure, yield 5.3 g.

The oximes were prepared by refluxing the ketones and NH₂OH·HCl in pyridine-EtOH (1:1, v/v) for 2 hr, decomposing the cooled reaction mixture with 3 N HCl, and extracting into Et₂O.

2-Amino-3-phenyl-1,1,1-trifluoropropane Hydrochlorides (Table III).—For example, a solution of 4-methoxybenzyl trifluoromethyl ketoxime (6.6 g, 0.028 mole) in dry Et₂O (100 ml) was added dropwise under N₂ to a stirred suspension of LiAlH₄ (1.2 g, 0.03 mole) in dry Et₂O (50 ml). The mixture was heated under reflux for 5 hr, and excess LiAlH₄ was destroyed (H₂O). Then 10% NaOH (100 ml) was added, the solid material was filtered off, and the Et₂O layer separated and was dried (MgSO₄). Removal of ether gave a yellow oil, from which the hydrochloride was prepared in ether-petroleum ether (bp 30–60°). Sublimation at 150–160° (1.0 mm) gave a colorless powder, yield 4.5 g.

Pharmacology. (a) Reversal of Reserpine Sedation in Mice.—All compounds (**1–6**) (Table III) were tested for amphetamine-like activity in reversing the reserpine-induced sedation in mice.¹⁴ In this test, reserpine (25 mg/kg) was injected subcutaneously to male albino mice; 2.5 hr later when all the animals were prostrate and unresponsive to stimuli, intraperitoneal

(5) R. M. Pinder and A. Burger, *J. Pharm. Sci.*, **56**, 970 (1967).

(6) M. Sletzing, personal communication.

(7) R. K. Ouellette, *J. Amer. Chem. Soc.*, **86**, 3089 (1964); M. E. Wolff and T. Jen, *J. Med. Chem.*, **6**, 726 (1963).

(8) A. Burger, S. E. Zimmerman, and E. J. Ariens, *ibid.*, **9**, 469 (1966).

(9) R. M. Pinder and A. Burger, unpublished work.

(10) G. P. Lewis, *Brit. J. Pharmacol.*, **9**, 488 (1954).

(11) E. B. Leffler, H. M. Spencer, and A. Burger, *J. Amer. Chem. Soc.*, **73**, 2611 (1951).

(12) S. Soloway and A. Lipschitz, *J. Org. Chem.*, **23**, 613 (1958).

(13) E. R. Bissell and M. Finger, *ibid.*, **24**, 1256 (1959).

(14) R. M. Burton, M. A. Sodd, and A. Goldin, *Arch. Int. Pharmacodyn. Ther.*, **112**, 188 (1957).

TABLE II
 BENZYL TRIFLUOROMETHYL KETONES

R	Yield, %	Bp (mm) or mp, °C	Formula ^a	Mp of oxime ^b , °C	Formula ^c
3-OCH ₃	60	73-77 (1.0)	C ₁₀ H ₉ F ₃ O ₂	55-56	C ₁₀ H ₉ F ₃ NO ₂
4-OCH ₃	68	67-70 (0.5)	C ₁₀ H ₉ F ₃ O ₂	51-52	C ₁₀ H ₉ F ₃ NO ₂
3,4-(OCH ₃) ₂	58	102-104 (0.7)	C ₁₁ H ₁₁ F ₃ O ₃	98-99	C ₁₁ H ₁₂ F ₃ NO ₃
3,5-(OCH ₃) ₂	27	66-67 ^b	C ₁₁ H ₁₁ F ₃ O ₃ ·2H ₂ O	91-92	C ₁₁ H ₁₂ F ₃ NO ₃
3,4,5-(OCH ₃) ₃	38	88-89 ^b	C ₁₂ H ₁₃ F ₃ O ₄ ·2H ₂ O	Not isolated	

^a All ketones were analyzed for C, H. Their ir and nmr spectra were as expected. ^b Recrystallized from C₆H₆-petroleum ether (bp 30-60°). ^c See footnote b, Table I.

 TABLE III
 2-AMINO-3-PHENYL-1,1,1-TRIFLUOROPROPANE HYDROCHLORIDES

No. ^a	R	Yield, %	Mp, °C	Recrystn solvent	Formula ^a	pK _a
2	3-OCH ₃	68	171-173	<i>i</i> -PrOH-petr ether ^c	C ₁₀ H ₁₂ F ₃ NO·HCl ^b	4.98
3	4-OCH ₃	71	188-190	Sublimed ^d	C ₁₀ H ₁₂ F ₃ NO·HCl	5.06
4	3,4-(OCH ₃) ₂	73	176-177	Sublimed ^d	C ₁₁ H ₁₄ F ₃ NO ₂ ·HCl	5.00
5	3,5-(OCH ₃) ₂	75	222-223	EtOH-petr ether ^c	C ₁₁ H ₁₄ F ₃ NO ₂ ·HCl	4.98
6	3,4,5-(OCH ₃) ₃	60	217-218	<i>i</i> -PrOH-petr ether ^c	C ₁₂ H ₁₆ F ₃ NO ₃ ·HCl	5.00

^a See footnote b, Table I. ^b C: calcd, 46.97; found, 46.43. ^c Bp 60-80°. ^d Compounds were sublimed at 150-160° (1.0 mm). ^e Compound 1 is 2-amino-3-phenyl-1,1,1-trifluoropropane hydrochloride, pK_a = 4.97.

injections of the drugs under study were given. Doses of *dl*-amphetamine of 5 mg/kg and above regularly reversed the effects of reserpine; the mice became alert and showed spontaneous activity. Doses of 40 mg/kg of 1-6 were completely without effect.

(b) **Production of Head Twitches in Mice.**—The method¹⁵ has been claimed to detect activity of drugs producing hallucinogenic effects in man. In this laboratory, subcutaneous doses of *dl*-amphetamine produce no characteristic head twitches in male albino mice while doses of mescaline of 5 mg/kg and above regularly produce an appreciable number of such twitches. Compounds 1-6 were used initially at 40 mg/kg but only 6 produced any head twitches. Assayed against mescaline in a six-point assay using ten mice per group, 6 showed a potency relative to mescaline of 0.11.

(c) **Neuropharmacological Action in Conscious Cats.**—Cats with chronically implanted stainless steel electrodes sited over association and auditory areas of the cortex were prepared according to the method of Bradley and Elkes.¹⁶ The animals were placed in a sound-proof chamber and their behavior was observed with the aid of closed circuit television. Electrocorical activity was recorded on an eight-channel Elema-Mingograph electroencephalograph. In the chamber the cats soon became drowsy and showed a characteristic pattern of electrocorical activity consisting of synchronized large-amplitude (1-3 cps) waves with bursts of spindle activity at 8-12 cps. A dose of *dl*-amphetamine (2 mg/kg ip) produced marked behavioral alerting and increased attentiveness. The alerting effect persisted for over 3 hr and during this period the EEG showed continuous, alert, desynchronized activity consisting of 15-30-cps low-amplitude waves. In this test, doses of up to 25 mg/kg of 1 or 6 caused no detectable change either in the behavior or in the electrocorical activity of the cats.

(d) **Actions in Cat Encephalé Isolé Preparations.**—The experiments were carried out according to the method of Bradley and Key,¹⁷ and enabled the effects of drugs on electrocorical and behavioral responses produced by electrical stimulation of the brain stem to be studied. A dose of *dl*-amphetamine (0.5 mg/kg iv) decreased both behavioral and electrocorical arousal thresholds by 50%. After a total dose of 1.0 mg/kg the preparation remained behaviorally alert and there was typical desynchro-

nized activity in the EEG. Total doses of 20 mg/kg of 1 or 6 had no effect in this test.

Acknowledgments.—We thank B. H. Butcher for help in the preparation of some key intermediates, D. B. Coult for pK_a determinations, and A. C. Thomas and his staff for microanalytical determinations.

Synthesis of Indole Hydrazines as Monoamine Oxidase Inhibitors^{1a}

K. SHANKER,^{1b} V. K. AGARWAL, R. J. SELVERAL, AND SURENDRA S. PARMAR^{1c}

Department of Pharmacology and Therapeutics,
King George's Medical College,
Lucknow University, Lucknow-3, India

Received June 11, 1968

Monoamine oxidase inhibitors have been reported to possess antidepressant² and pronounced anticonvulsant properties.³ In addition, clinical efficacy of 3-(2-aminobutyl)indole for the treatment of some types of depression⁴ and its ability to inhibit reversibly rat brain and rat liver monoamine oxidase⁵ led us to synthesize substituted indoleacyl hydrazides as compounds affecting the activity of the central nervous system.

(1) (a) The investigation was supported in part by the Council of Scientific and Industrial Research, New Delhi, and the State Council of Scientific and Industrial Research, Lucknow (Junior Research Fellowship to V. K. A.).

(b) Postdoctoral Research Fellow of the Council of Scientific and Industrial Research. (c) Enquiries should be addressed to Professor S. S. Parmar.

(2) E. A. Zeller, S. Sarkar, R. Banerjee, and M. S. Ise, *Helv. Chim. Acta*, **43**, 439 (1960).

(3) D. J. Prockop, P. A. Shore, and B. B. Brodie, *Ann. N. Y. Acad. Sci.*, **80**, 643 (1959).

(4) L. J. Meduna, *J. Neuropsychiat., Suppl.*, **2**, 150 (1961).

(5) M. E. Grieg, P. H. Seay, and W. A. Freyburger, *ibid.*, **2**, 131 (1961).

(15) S. J. Currie and R. W. Pickering, *Psychopharmacologia*, **11**, 65 (1967).

(16) P. B. Bradley and J. Elkes, *Brain*, **80**, 77 (1957).

(17) P. B. Bradley and B. J. Key, *EEG Clin. Neurophysiol.*, **10**, 97 (1958).